Abstract:This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, a… Show more
The hepatitis C virus (HCV) core protein (HCVcp) is the most highly conserved protein encoded by the HCV genome, and its N-terminal domain (
NTD
HCVcp) plays a crucial role in nucleocapsid assembly. Together, these two features make it an attractive target for antiviral therapeutics. However,
NTD
HCVcp is intrinsically disordered, leading to a high degree of conformational heterogeneity, and given its essential role in nucleocapsid assembly, it also tends to oligomerize at high concentrations, both of which make it difficult to characterize heterotypic intermolecular interactions between monomeric
NTD
HCVcp and potential therapeutics using conventional structure-based approaches. Here, we use single-molecule FRET spectroscopy to overcome these challenges and study the structural and energetic aspects of binding interactions involving different viral genotypes of
NTD
HCVcp and antiviral therapeutics based on antibodies, aptamers, peptides, and small molecules. Our findings highlight distinct binding mechanisms associated with these molecular interactions. For example, binding of high-affinity antibodies does not perturb the end-to-end distance of
NTD
HCVcp and is weakly impeded by electrostatic repulsions between similarly charged residues. Conversely, the low-nanomolar equilibrium dissociation constants of antiviral DNA aptamers arise from strong attractive electrostatic interactions that greatly decrease the end-to-end distance of
NTD
HCVcp. Furthermore, low-affinity antiviral peptides promote oligomerization of
NTD
HCVcp. Finally, the small-molecule antiviral compound we studied does not appear to affect any of our experimental observables, suggesting that binding may not alter the conformational properties of
NTD
HCVcp.
IMPORTANCE
The hepatitis C virus is associated with nearly 300,000 deaths annually. At the core of the virus is an RNA-protein complex called the nucleocapsid, which consists of the viral genome and many copies of the core protein. Because the assembly of the nucleocapsid is a critical step in viral replication, a considerable amount of effort has been devoted to identifying antiviral therapeutics that can bind to the core protein and disrupt assembly. Although several candidates have been identified, little is known about how they interact with the core protein or how those interactions alter the structure and thus the function of this viral protein. Our work biochemically characterizes several of these binding interactions, highlighting both similarities and differences as well as strengths and weaknesses. These insights bolster the notion that this viral protein is a viable target for novel therapeutics and will help to guide future developments of these candidate antivirals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.